Bellevue Life Sciences Acquisition Corp. Quarterly Income Tax Expense (Benefit) in USD from Q1 2023 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Bellevue Life Sciences Acquisition Corp. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q1 2023 to Q3 2024.
  • Bellevue Life Sciences Acquisition Corp. Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was $46K, a 64.6% decline year-over-year.
  • Bellevue Life Sciences Acquisition Corp. Income Tax Expense (Benefit) for the twelve months ending September 30, 2024 was $377K.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $377K $46K -$83.9K -64.6% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 $461K $87.3K -$141K -61.8% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-19
Q1 2024 $602K $90.5K +$61.2K +209% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 $541K $153K Oct 1, 2023 Dec 31, 2023 10-K 2024-04-17
Q3 2023 $130K Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 $229K Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-19
Q1 2023 $29.3K Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.